Australian researchers have discovered that men with incurable prostate cancer, but without symptoms, who received immediate hormone treatment on the TROG 03.06 (TOAD) clinical trial, had an increase in survival over those who delayed treatment – with 80% still alive after six years, compared to 65% of men for whom treatment was delayed until they…
For the first time, a large randomized trial has suggested that overall survival is improved by the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in men with localized, high-risk, hormone-sensitive prostate cancer. Docetaxel has been used to treat metastatic hormone-resistant prostate cancer for a number of years, and this new study—RTOG 0521—suggests that…
Too many men are getting the all-clear for prostate cancer when in fact they have the disease, say doctors, who are calling for an overhaul of testing techniques. Professor Stephen Langley, a prostate cancer expert, blames the misdiagnoses on inaccurate biopsies. Under current guidelines from NICE (National Institute for Health and Care Excellence), men with…
A central challenge in diagnosing and treating prostate cancer is distinguishing fast from slow, aggressive from indolent. Consider the experience of Gerald Alexander. A former Air Force surgical service specialist who completed several tours of duty in Iraq and Afghanistan, Alexander was preparing to retire from the military and make a transition to teaching high…
ROCHESTER, N.Y. — Hans Schmitthenner, a research scientist at Rochester Institute of Technology, hopes to make detecting prostate cancer — the second leading cause of cancer deaths among men — less of a guessing game. Non-cancerous cells as well as cancerous cells can produce elevated PSA levels in the test for prostate-specific antigens commonly used…